A-C, Western blot analysis of caspase activation. HIV-1 PV infected MDM cells were treated with either 250 ng/ml rsTRAIL (A) or 250 ng/ml AD5-10 (B) or 250 ng/ml rsTRAIL plus 250 ng/ml AD5-10 (C) for 2, 4, 6 and 8 hr. The cells were lysed and the lysates were subjected to SDS-PAGE and immunoblotting with anti-caspase -3, -8, or -9 antibody. D–E, cell viability determined by MTS. HIV-1 PV infected MDM were treated with 500 ng/ml rsTRAIL (D) or 500 ng/ml AD5-10 (E) or 250 ng/ml rsTRAIL plus 250 ng/ml AD5-10 (F) in the absence or presence of 50 µM of Z-VAD-fmk for 12 hr. Values are mean of three independent experiments with error bar representing standard deviation of the mean. *, p<0.05; **, p<0.01; ***, p<0.001; ns, no significant.